DeepMed Research

Cinacalcet

Generic Name: Cinacalcet

Brand Names: Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₂F_₃N

CAS Number: 226256-56-0

Unique Ingredient Identifier: UAZ6V7728S

Background: Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

Indication: For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Associated Conditions: Hypercalcemia, Secondary Hyperparathyroidism (SHPT)

Clinical Trials

The Trial of SHR6508 in Secondary Hyperparathyroidism

Phase 3

Active, not recruiting

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: Cinacalcet plus intravenous placebo
Drug: SHR6508 plus oral placebo tablets

First Posted Date: 2024-05-30

Last Posted Date: 2025-05-04

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 498

Registration Number: NCT06434961

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis

Phase 4

Completed

Conditions: Drug Effect

Interventions: Drug: Cinacalcet

First Posted Date: 2023-07-03

Last Posted Date: 2024-01-24

Lead Sponsor: Tanta University

Target Recruit Count: 35

Registration Number: NCT05926570

Locations: 🇪🇬
Sara Mabrouk Mohamed Elghoul, Tanta, Egypt

A Study of SHR6508 in Secondary Hyperparathyroidism

Phase 2

Active, not recruiting

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: SHR6508
Drug: Cinacalcet

First Posted Date: 2022-12-23

Last Posted Date: 2023-06-18

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 75

Registration Number: NCT05663411

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment

Not Applicable

Completed

Conditions: Hyperparathyroidism; Secondary, Renal

Interventions: Drug: Cinacalcet Tablets
Drug: calcitriol

First Posted Date: 2020-11-19

Last Posted Date: 2020-11-19

Lead Sponsor: Min-Sheng General Hospital

Target Recruit Count: 40

Registration Number: NCT04637360

Locations: 🇨🇳
Min sheng general hospital, Taoyuan city, Taiwan

Novel Combination Therapy for Osteoporosis in Men

Phase 4

Active, not recruiting

Conditions: Male Osteoporosis

Interventions: Drug: Teriparatide or human parathyroid hormone (PTH) 1-34
Drug: placebo tablet
Drug: Cinacalcet
Dietary Supplement: Calcium citrate tablet
Dietary Supplement: Vitamin D3

First Posted Date: 2019-06-21

Last Posted Date: 2024-08-19

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 40

Registration Number: NCT03994172

Locations: 🇺🇸
San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Phase 3

Completed

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: Cinacalcet Hydrochloride
Drug: KHK7580

First Posted Date: 2019-01-30

Last Posted Date: 2022-04-25

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 404

Registration Number: NCT03822507

Locations: 🇨🇳
Research site_3, Kaohsiung, Taiwan
🇨🇳
Research site_5, Kaohsiung, Taiwan
🇨🇳
Research site_6, Taipei, Taiwan

and more 31 locations

Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)

Phase 2

Completed

Conditions: Primary Hyperparathyroidism

Interventions: Drug: Placebo
Drug: Cinacalcet

First Posted Date: 2018-12-14

Last Posted Date: 2018-12-14

Lead Sponsor: Amgen

Target Recruit Count: 10

Registration Number: NCT03776058

Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism

Phase 2

Completed

Conditions: Primary Hyperparathyroidism

Interventions: Drug: Placebo
Drug: Cinacalcet

First Posted Date: 2018-12-13

Last Posted Date: 2018-12-13

Lead Sponsor: Amgen

Target Recruit Count: 48

Registration Number: NCT03774771

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

Phase 3

Completed

Conditions: Secondary Hyperparathyroidism
Chronic Kidney Disease

Interventions: Drug: Cinacalcet
Drug: Etelcalcetide

First Posted Date: 2017-10-03

Last Posted Date: 2021-04-30

Lead Sponsor: Amgen

Target Recruit Count: 637

Registration Number: NCT03299244

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

Phase 4

Completed

Conditions: Hyperparathyroidism; Secondary, Renal

Interventions: Drug: Cinacalcet HCl

First Posted Date: 2017-04-21

Last Posted Date: 2024-04-29

Lead Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd.

Target Recruit Count: 750

Registration Number: NCT03123406

Locations: 🇨🇳
Nanjing Jinling Hospital, Nanjing, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy